Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kuvan Therapy in Phenylketonuria (PKU)
NCT00841100Phase 2Completed
- Sponsor
- University of Miami
- Start
- Dec 2008
- Primary completion
- Jul 2011
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of sapropterin in phenylketonuria (PKU) (4 arms), sponsored by University of Miami. Primary endpoint: Percent Change in Blood Phenylalanine at Day 28. Started Dec 2008; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT00841100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841100.